Preparation, Relative Toxicity, Chemotherapeutic Activity, and Pharmacokinetics of Liposomal SJA-95: A New Polyene Macrolide Antibiotic

Desai, Sandhya K.; Naik, Suresh R.

doi:10.1080/08982100802457336

Cited by 2 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To obtain increased therapeutic efficacy, a drug carrier must achieve increased delivery of the drug to the tumor tissue, while also allowing for enhanced interaction of the drug with, and subsequent internalization by, tumor cells. Liposomes, as carriers of chemotherapeutic agents, are able to change the distribution of these agents within the body and decrease their toxicity [23,24]. Therefore, drug-loaded liposomes offer a new approach for the treatment of colorectal cancer.…”

Section: Discussionmentioning

confidence: 99%

Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma

Yang

Liu

et al. 2011

BMC Biotechnol

View full text Add to dashboard Cite

BackgroundCytotoxic drugs are non-selective between normal and pathological tissue, and this poses a challenge regarding the strategy for treatment of tumors. To achieve sufficient antitumor activity for colorectal carcinoma, optimization of the therapeutic regimen is of great importance. We investigated the ability of oxaliplatin long-circulating liposomes (PEG-liposomal L-oHP) to provide an improved therapeutic index of colorectal carcinoma.ResultsWe determined that PEG- liposomes conjugated with cells at 2 h, with a mean fluorescence intensity that was enhanced upon extended induction time. The PEG-liposomal L-oHP induced a significant apoptotic response as compared with free L-oHP, 23.21% ± 3.38% vs. 16.85% ± 0.98%, respectively. Fluorescence imaging with In-Vivo Imaging demonstrated that PEG- liposomes specifically targeted tumour tissue. After intravenous injections of PEG-liposomal L-oHP or free L-oHP, the tumour volume suppression ratio was 26.08% ± 12.43% and 18.19% ± 7.09%, respectively, the percentage increased life span (ILS%) was 45.36% and 76.19%, respectively, and Bcl-2, Bax mRNA and protein expression in tumour tissue was 0.27-fold vs. 0.88-fold and 1.32-fold vs. 1.61-fold compared with free L-oHP, respectively.ConclusionThe PEG-liposomal L-oHP exhibited a tendency to target tumour tissue and demonstrated a significantly greater impact on apoptosis compared to free oxaliplatin.

show abstract

Section: Discussionmentioning

confidence: 99%

Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma

Yang

Liu

et al. 2011

BMC Biotechnol

View full text Add to dashboard Cite

show abstract

“…S-24, has shown some promising antifungal activity in vitro against yeasts, filamentous fungi, and clinical isolates, including plant pathogens (Naik et al 2007). Studies have indicated that Lip SJA-95 treatment led to prolonged survival time, effective microbiological clearance, and reduced toxicity in the mice model of Candidiasis (Desai and Naik 2008b). Studies have indicated that Lip SJA-95 treatment led to prolonged survival time, effective microbiological clearance, and reduced toxicity in the mice model of Candidiasis (Desai and Naik 2008b).…”

Section: Liposomal Formulationsmentioning

confidence: 99%

Novel Drug Delivery Systems for Antifungal Compounds

Zia

Farzuddin

Ansari

et al. 2010

Combating Fungal Infections

View full text Add to dashboard Cite

Development of new approaches for treatment of invasive fungal infections encompasses new delivery systems for approved and investigational compounds. Novel delivery systems consisting of cyclodextrins (CDs), cochleates, nanoparticles, and long-circulating ("stealth") liposomes modulate the pharmacokinetics of existing drugs, and may also be useful to enhance the delivery of antifungal agents to sites of infection. Among several promising new drug-delivery systems, liposomes represent an advanced technology for site-directed delivery of active molecules. Research on liposome technology has progressed from conventional vesicles ("first-generation liposomes") to "second-generation liposomes", in which long-circulating liposomes are obtained by modifying the surface of liposomes using several molecules, such as glycolipids, sialic acid, or synthetic polymer poly-(ethylene glycol) (PEG), resulting in prolonged reticulo-endothelial system uptake and serum half-life, thus increasing the therapeutic efficacy of drugs. At present, several formulations for amphotericin B are in clinical use for fungal infections in Europe and the United States. Nanoformulations have also been applied as drug delivery systems (DDSs), with great success. Finally, progress in the design of DDSs has led to the development of carriers targeted to specific tissues and cells. Efforts are now going on to improve their stability in the biological environment, to mediate the biodistribution of active compounds, and to improve drug loading, targeting, transport, release, and interaction with biological barriers. This chapter discusses the state of the art in the field of DDSs, used for control of systemic fungal infections.

show abstract

Preparation, Relative Toxicity, Chemotherapeutic Activity, and Pharmacokinetics of Liposomal SJA-95: A New Polyene Macrolide Antibiotic

Cited by 2 publications

References 18 publications

Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma

Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma

Novel Drug Delivery Systems for Antifungal Compounds

Contact Info

Product

Resources

About